Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uropathogenic E. coli Avidocin
- Development stage
- Preclinical
- Lead developer
- Pylum Biosciences
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral, Parenteral
01
Overview
Uropathogenic E. coli Avidocin is a preclinical-stage antibacterial agent being developed by Pylum Biosciences (formerly AvidBiotics) for the treatment of recurrent urinary tract infections (rUTIs). The drug belongs to Pylum's proprietary Avidocin™ platform, which consists of engineered R-type bacteriocins (pyocins). These are naturally occurring defensive proteins of bacteria that have been re-engineered to selectively recognize and kill specific bacterial pathogens. Uropathogenic E. coli Avidocin is precisely engineered to target and kill uropathogenic Escherichia coli (UPEC) while leaving healthy gut and urinary microbiota undisturbed. Unlike traditional broad-spectrum antibiotics, Avidocin proteins employ a narrow-spectrum, bactericidal killing mechanism that bypasses conventional antibiotic resistance strategies. Preclinical studies have demonstrated efficacy in infection models via oral or parenteral administration.
- Other names
- Avidocin vs. Uropath. E. coliUropathogenic E.coli Avidocin
Beyond the preview
Go deeper on Uropathogenic E. coli Avidocin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Uropathogenic E. coli Avidocin.